JP2011530521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011530521A5 JP2011530521A5 JP2011522195A JP2011522195A JP2011530521A5 JP 2011530521 A5 JP2011530521 A5 JP 2011530521A5 JP 2011522195 A JP2011522195 A JP 2011522195A JP 2011522195 A JP2011522195 A JP 2011522195A JP 2011530521 A5 JP2011530521 A5 JP 2011530521A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- disorder
- use according
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- -1 4-bromo-3,5-dimethoxyphenyl Chemical group 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000006373 Bell palsy Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035548 disruptive behavior disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8640608P | 2008-08-05 | 2008-08-05 | |
| US61/086,406 | 2008-08-05 | ||
| US11808808P | 2008-11-26 | 2008-11-26 | |
| US61/118,088 | 2008-11-26 | ||
| US21831109P | 2009-06-18 | 2009-06-18 | |
| US61/218,311 | 2009-06-18 | ||
| PCT/US2009/052754 WO2010017236A1 (en) | 2008-08-05 | 2009-08-04 | Pde10 inhibitors and related compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011530521A JP2011530521A (ja) | 2011-12-22 |
| JP2011530521A5 true JP2011530521A5 (enExample) | 2012-09-13 |
| JP5759893B2 JP5759893B2 (ja) | 2015-08-05 |
Family
ID=41653504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522195A Active JP5759893B2 (ja) | 2008-08-05 | 2009-08-04 | Ｐｄｅ１０阻害剤ならびに関連する組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8377930B2 (enExample) |
| EP (1) | EP2310016B1 (enExample) |
| JP (1) | JP5759893B2 (enExample) |
| CN (1) | CN102143752B (enExample) |
| AU (1) | AU2009279756B2 (enExample) |
| CA (1) | CA2733378C (enExample) |
| ES (1) | ES2654617T3 (enExample) |
| NZ (1) | NZ590951A (enExample) |
| WO (1) | WO2010017236A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| ES2654617T3 (es) | 2008-08-05 | 2018-02-14 | Omeros Corporation | Inhibidores de PDE10 y composiciones y procedimientos relacionados |
| FR2936784B1 (fr) | 2008-10-08 | 2010-10-08 | Gaztransp Et Technigaz | Cuve a membrane ondulee renforcee |
| ES2742195T3 (es) * | 2010-03-12 | 2020-02-13 | Omeros Corp | Inhibidores de PDE10 y composiciones y métodos relacionados |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| CA2824047C (en) | 2011-01-11 | 2019-06-18 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
| JP5955531B2 (ja) * | 2011-11-07 | 2016-07-20 | 千葉県 | 抗癌剤 |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| NZ716494A (en) * | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| AU2016250843A1 (en) | 2015-04-24 | 2017-10-12 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| EP3468546A4 (en) | 2016-06-09 | 2020-04-01 | Cedars-Sinai Medical Center | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2615188B1 (fr) | 1987-05-14 | 1989-11-17 | Meram Laboratoires Sa | Derives d'hydrazine, procede d'obtention et compositions pharmaceutiques les contenant |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| EP1272463A1 (en) | 2000-01-28 | 2003-01-08 | Rohm And Haas Company | Enhanced propertied pharmaceuticals |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| GB0223665D0 (en) | 2002-10-10 | 2002-11-20 | Syngenta Participations Ag | Organic compounds |
| DE10346913A1 (de) * | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
| CA2553848A1 (en) * | 2004-01-21 | 2005-08-04 | Cornell Research Foundation, Inc. | Chemical inhibitors of soluble adenylyl cyclase (sac) |
| CN1929831A (zh) | 2004-03-08 | 2007-03-14 | 默克专利有限公司 | 改变胰岛素分泌的方法 |
| AU2005229497A1 (en) | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for interfering with fibrosis |
| BRPI0508574A (pt) | 2004-03-11 | 2007-08-14 | Merck Patent Gmbh | métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides |
| JP2008540424A (ja) | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ｓＥＨインヒビターとしてのアシルヒドラゾンの使用方法 |
| WO2008064342A2 (en) * | 2006-11-21 | 2008-05-29 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US7786139B2 (en) * | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009143178A2 (en) | 2008-05-20 | 2009-11-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| ES2654617T3 (es) | 2008-08-05 | 2018-02-14 | Omeros Corporation | Inhibidores de PDE10 y composiciones y procedimientos relacionados |
| ES2742195T3 (es) | 2010-03-12 | 2020-02-13 | Omeros Corp | Inhibidores de PDE10 y composiciones y métodos relacionados |
-
2009
- 2009-08-04 ES ES09805466.1T patent/ES2654617T3/es active Active
- 2009-08-04 WO PCT/US2009/052754 patent/WO2010017236A1/en not_active Ceased
- 2009-08-04 US US12/535,598 patent/US8377930B2/en active Active
- 2009-08-04 CN CN200980134364.6A patent/CN102143752B/zh active Active
- 2009-08-04 JP JP2011522195A patent/JP5759893B2/ja active Active
- 2009-08-04 EP EP09805466.1A patent/EP2310016B1/en active Active
- 2009-08-04 CA CA2733378A patent/CA2733378C/en active Active
- 2009-08-04 AU AU2009279756A patent/AU2009279756B2/en active Active
- 2009-08-04 NZ NZ590951A patent/NZ590951A/xx unknown
-
2013
- 2013-01-15 US US13/742,199 patent/US9783521B2/en active Active
-
2017
- 2017-09-01 US US15/694,342 patent/US20180118711A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011530521A5 (enExample) | ||
| NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2009538910A5 (enExample) | ||
| RU2012143610A (ru) | Pde10 ингибиторы и содержащие их композиции и способы | |
| JP2014051526A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| JP2014526469A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2020517607A5 (enExample) | ||
| JP2010520265A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| JP2019529490A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2010540509A5 (enExample) | ||
| JP2019532079A5 (enExample) | ||
| RU2014145682A (ru) | Органические соединения | |
| JP2011515482A5 (enExample) | ||
| JP2009527462A5 (enExample) | ||
| JP2012502111A5 (enExample) | ||
| JP2014526435A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2018519329A5 (enExample) | ||
| JP2009531277A5 (enExample) |